Evaluating the effect of Neoadjuvant chemotherapy for esophageal Cancer using the RECIST system with shorter-axis measurements: a retrospective multicenter study

Table 3 Cox regression analysis of overall survival

Characteristic	Univariate analysis		Multivariate analysis
Characteristic	HR (95% CI)	P-value	HR (95% CI)	P-value
Age, years	1.15 (1.002–1.053)	0.037	1.06 (1.030–1.085)	< 0.001
Sex, male (vs. female)	1.41 (0.800–2.561)	0.232
Performance status, 0 (vs. 1–2)	0.88 (0.593–1.313)	0.537
NAC regimen, platinum-based (vs. taxane-based)	0.84 (0.591–1.194)	0.332
RECIST classification by longest diameter; PR (vs. SD + PD)	0.68 (0.474–0.979)	0.038	1.15 (0.764–1.731)	0.501
RECIST classification by shorter axis; PR (vs. SD + PD)	0.40 (0.278–0.588)	< 0.001	0.56 (0.363–0.856)	0.008
RECIST classification by multiplication of longest diameter by shorter axis; PR (vs. SD + PD)	0.50 (0.344–0.720)	< 0.001	Inappropriate for multivariate analysis
Histological type Squamous cell carcinoma (vs. others)	0.93 (0.512–1.683)	0.806
TRG, ≥1b (vs. 0–1a)	0.26 (0.162–0.421)	< 0.001	0.35 (0.215–0.580)	< 0.001
Pathological stage 0–II (vs. III + IV)	0.31 (0.209–0.460)	< 0.001	0.32 (0.213–0.490)	< 0.001

Abbreviations: CDC Clavien–Dindo classification, CI confidence interval; HR, hazard ratio, NAC neoadjuvant chemotherapy, PD progressive disease, PR partial response, RECIST Response Evaluation Criteria in Solid Tumors, SD stable disease, TRG tumor regression grade

ISSN: 1471-2407